Global markets have recently shown mixed performances, with the S&P 500 and Nasdaq Composite both closing out a strong year despite some volatility and profit-taking towards year-end. In this ...

ET Net News Agency, 8 January 2025] A direct manual trade of 1.67 million shares of INNOVENT BIO (01801) was registered at 1:00p.m. The deal amounted to HK$56.6m, or at HK$33.8 p ...

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

China’s National Medical Products Administration (NMPA) has approved the second New Drug Application (NDA) of Dovbleron ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...

IBI-354 is under development for the treatment of solid tumors, breast cancer, ovarian cancer, endometrial cancer and colorectal cancer. The drug candidate is a recombinant anti-HER2 monoclonal ...

China NMPA approves Innovent Biologics’ Dovbleron to treat ROS1-positive non-small cell lung cancer: San Francisco Saturday, January 4, 2025, 14:00 Hrs [IST] Innovent Biologics, ...

Innovent has submitted a second new drug application (NDA) to China's National Medical Products Administration (NMPA) seeking approval for Dovbleron as a treatment for ROS1-positive advanced NSCLC ...

In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.

CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satricabtagene autoleucel (satri-cel) has shown efficacy in gastric cancer, in a rare win for this type of cell therapy in a solid ...

Innovent Biologics (IVBIY) secures second Chinese approval for lung cancer therapy Dovbleron developed with U.S. biotech ...

Innovent inks exclusive global license agreement with Roche to advance the development of IBI3009, a novel DLL3 targeted ADC candidate: San Francisco, US Friday, January 3, 2025, ...